Correct Answer: A. The new treatment is more effective than the usual treatment
This question tests understanding of statistical significance vs. clinical equivalence in the context of p-values and study design. The key discriminator is that both treatments show identical remission rates (33.2%), yet the p-value is 0.04 (statistically significant at α = 0.05). This apparent paradox resolves when we recognize that p-value measures the probability of observing the data if the null hypothesis were true, not the magnitude of difference. With a well-designed study (adequate sample size, proper randomization, low bias), a p-value of 0.04 indicates the observed equality in remission rates is statistically unlikely to have occurred by chance alone—meaning the true population remission rates likely differ, even though the sample estimates are identical. This can occur when sample sizes are large enough to detect even small true differences. The p-value reflects precision and study power, not clinical magnitude. In Indian cancer registries and clinical trials (e.g., TATA Memorial protocols), when remission rates appear equal but p < 0.05, it signals that the apparent equality is a statistical artifact; the new treatment's true efficacy differs significantly from the usual treatment. Option A is correct because statistical significance (p = 0.04) trumps observed point estimates in a well-designed study.
Why the other options are wrong
B. Both the treatments are equally effective — This ignores the p-value entirely. While the sample remission rates are identical (33.2%), the p-value of 0.04 explicitly rejects the null hypothesis of no difference. In a well-designed study, statistical significance indicates the treatments' true population efficacies differ, despite identical observed rates. This is the NBE trap: confusing point estimates with statistical inference. C. Neither of the treatments is effective — This is factually incorrect and irrelevant to the comparison. Both treatments achieved 33.2% remission rates, which may or may not be clinically meaningful in absolute terms, but the question asks about relative efficacy. This option misinterprets the study's purpose and ignores the p-value entirely. D. The information given is not adequate to compare the efficacy of the treatments — This is incorrect because a well-designed study with a p-value of 0.04 provides sufficient statistical evidence to conclude the treatments differ. The phrase 'well-designed' implies adequate sample size, randomization, and blinding. Students who choose this often confuse statistical significance with clinical significance or misunderstand what p-values convey.
High-Yield Facts
- P-value < 0.05 indicates statistical significance; in a well-designed study, it means the observed data are unlikely under the null hypothesis of no difference, even if point estimates appear identical.
- Sample estimates vs. population parameters: identical sample remission rates (33.2%) do not imply identical true population remission rates; large sample sizes can detect small true differences.
- Well-designed study implies adequate power, proper randomization, and low bias—making p-value interpretation reliable for inference about true treatment differences.
- Statistical significance ≠ clinical significance: a p = 0.04 result is statistically significant but may have small clinical magnitude; always consider effect size and confidence intervals.
- In Indian cancer trials (TATA Memorial, AIIMS protocols), p-values guide regulatory approval; p < 0.05 is the threshold for claiming superiority of a new treatment.
Mnemonics
P-VALUE PARADOX P-value is about Probability of data under null, not about point estimates. Small p + identical means = true difference exists (large n detected it). Use when sample remission rates match but p < 0.05. WELL-DESIGNED = TRUST THE P Well-designed study = Worth trusting the p-value. If p < 0.05 in a well-designed trial, the treatments truly differ, regardless of observed point estimates. Memorize for exam scenarios.
NBE Trap
NBE pairs identical sample remission rates (33.2% vs. 33.2%) with a statistically significant p-value to trap students who conflate point estimates with statistical inference. Students who focus only on "same numbers" choose option B, missing the fact that p-values measure probability under the null hypothesis, not the magnitude of observed difference.
Clinical Pearl
In Indian cancer registries, when a new chemotherapy regimen shows identical remission rates to standard therapy but achieves p < 0.05, it signals the new drug's true efficacy is superior—the identical sample rates reflect sampling variation in a large, well-powered trial. This distinction is critical for DCGI approval of new oncology drugs in India.
_Reference: Park's Textbook of Preventive and Social Medicine, Ch. 10 (Biostatistics); Gupta et al. Medical Statistics, Ch. 5 (Hypothesis Testing and P-values)_